Elucid Overview
- Status
-
Private
- Employees
-
147
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$55M
- Investors
-
20
Elucid General Information
Description
Developer of an imaging system designed to improve patient outcomes at a reduced cost by applying artificial intelligence to vascular diagnostic imaging. The company's system objectively quantifies the extent and stability of arterial plaque and offers an economically efficient and non-invasive method for capturing patient health information, enabling cardiovascular pathologists to enhance patient care and provide comprehensive and accurate clinical insights.
Contact Information
Website
www.elucid.comCorporate Office
- 399 Boylston Street
- Suite 400
- Boston, MA 02116
- United States
Corporate Office
- 399 Boylston Street
- Suite 400
- Boston, MA 02116
- United States
Elucid Timeline
Elucid Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series D) | 02-Sep-2026 | $55M | Completed | Generating Revenue | ||
| 9. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 18-Oct-2023 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 28-Mar-2023 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A) | 10-Dec-2020 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jun-2019 | Completed | Generating Revenue | |||
| 4. Seed Round | 22-Feb-2019 | Completed | Startup | |||
| 3. Grant | 01-Jan-2015 | Completed | Startup | |||
| 2. Angel (individual) | 31-Dec-2013 | $375K | $375K | Completed | Startup | |
| 1. Grant | 01-Aug-2013 | $3M | Completed | Startup |
Elucid Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | 2,319,244 | $0.000100 | $1.1 | $1.1 | 1x | $1.1 | 1.62% | |
| Series A1 | 2,534,907 | $0.000100 | $0.71 | $0.71 | 1x | $0.71 | 1.77% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Elucid Comparisons
Industry
Financing
Details
Elucid Competitors (30)
One of Elucid’s 30 competitors is Advantis Medical Imaging, a Venture Capital-Backed company based in Eindhoven, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Advantis Medical Imaging | Venture Capital-Backed | Eindhoven, Netherlands | ||||
| Amiko | Venture Capital-Backed | Milan, Italy | ||||
| Aidoc | Venture Capital-Backed | New York, NY | ||||
| Medipixel | Venture Capital-Backed | Seoul, South Korea | ||||
| Quibim | Venture Capital-Backed | Valencia, Spain |
Elucid Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Elucid Patents
Elucid Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4616427-A1 | Structured representations for interpretable machine learning applications in medical imaging | Pending | 09-Nov-2022 | ||
| EP-4616427-A4 | Structured representations for interpretable machine learning applications in medical imaging | Pending | 09-Nov-2022 | ||
| US-12154321-B2 | Structured representations for interpretable machine learning applications in medical imaging | Active | 09-Nov-2022 | ||
| US-20240153252-A1 | Structured representations for interpretable machine learning applications in medical imaging | Active | 09-Nov-2022 | ||
| US-20250037437-A1 | Structured representations for interpretable machine learning applications in medical imaging | Pending | 09-Nov-2022 | G06V10/774 |
Elucid Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Elucid Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Elevage Medical Technologies | Growth/Expansion | Minority | ||
| Unorthodox Ventures | Venture Capital | Minority | ||
| Aphelion Capital | Venture Capital | Minority | ||
| Biovision Ventures | Venture Capital | Minority | ||
| Philips Ventures | Corporate Venture Capital | Minority |
Elucid FAQs
-
Where is Elucid headquartered?
Elucid is headquartered in Boston, MA.
-
What is the size of Elucid?
Elucid has 147 total employees.
-
What industry is Elucid in?
Elucid’s primary industry is Decision/Risk Analysis.
-
Is Elucid a private or public company?
Elucid is a Private company.
-
What is the current valuation of Elucid?
The current valuation of Elucid is .
-
What is Elucid’s current revenue?
The current revenue for Elucid is .
-
How much funding has Elucid raised over time?
Elucid has raised $182M.
-
Who are Elucid’s investors?
Elevage Medical Technologies, Unorthodox Ventures, Aphelion Capital, Biovision Ventures, and Philips Ventures are 5 of 20 investors who have invested in Elucid.
-
Who are Elucid’s competitors?
Advantis Medical Imaging, Amiko, Aidoc, Medipixel, and Quibim are some of the 30 competitors of Elucid.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
